Clinical Trials Logo

Colonic Neoplasms clinical trials

View clinical trials related to Colonic Neoplasms.

Filter by:

NCT ID: NCT00055848 Completed - Colorectal Cancer Clinical Trials

Genetic Study of Familial Factors in Patients With Colon Cancer

Start date: December 2001
Phase: N/A
Study type: Observational

RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Clinical trial to study the cancer-related genes in patients who have colon cancer or adenomatous polyps.

NCT ID: NCT00054912 Completed - Clinical trials for Colorectal Neoplasms

An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

Start date: February 2003
Phase: Phase 1
Study type: Interventional

EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.

NCT ID: NCT00041652 Completed - Breast Cancer Clinical Trials

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Start date: February 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.

NCT ID: NCT00040599 Completed - Colorectal Cancer Clinical Trials

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Start date: January 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.

NCT ID: NCT00035087 Completed - Clinical trials for Colorectal Neoplasms

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Start date: May 2002
Phase: Phase 2
Study type: Interventional

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.

NCT ID: NCT00023933 Completed - Clinical trials for Recurrent Rectal Cancer

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Start date: October 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective treatment for colorectal cancer

NCT ID: NCT00020267 Completed - Breast Cancer Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Cancer

Start date: July 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.

NCT ID: NCT00019760 Completed - Liver Metastases Clinical Trials

Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver

Start date: April 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of melphalan given as an isolated hepatic perfusion followed by chemotherapy infused into the liver in patients who have unresectable colorectal cancer that is metastatic to the liver.

NCT ID: NCT00019006 Completed - Clinical trials for Recurrent Rectal Cancer

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Start date: March 1995
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.

NCT ID: NCT00005979 Completed - Colorectal Cancer Clinical Trials

Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer

Start date: July 22, 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without irinotecan in treating colon cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without irinotecan in treating patients who have stage III colon cancer.